Neoantigen based cancer vaccine - Imunon
Alternative Names: IP-Y; IP-Y - ImunonLatest Information Update: 30 Jun 2025
At a glance
- Originator Imunon
- Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 25 Apr 2025 Preclinical trials in Cancer in USA prior to April 2025 (IM)
- 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 09 May 2023 Early research in Cancer in USA (unspecified route) before May 2023 (Imunon pipeline, May 2023)